Biomedical device company Biotronik said the U.S. Food and Drug Administration (FDA) has cleared its MultiPole Pacing (MPP) technology, providing physicians with additional treatment options for heart failure patients who have been nonresponsive to cardiac resynchronization therapy (CRT).
The technology will be available on new Biotronik CRT defibrillator (CRT-D) systems for patients with heart failure. MPP enables the left ventricle to be paced twice per cardiac cycle either sequentially or simultaneously, the company said.
Biotronik CRT-D devices also feature ProMRI technology and are equipped with MRI AutoDetect, a dedicated sensor that detects the MRI environment, converts the patient's device to MRI mode, and then automatically returns to its permanent program when the scan is complete.
